Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
FREQUENCY OF THE VARIANT ALLELE CYP2D6(C) AMONG NORTH-AMERICAN CAUCASIAN LUNG-CANCER PATIENTS AND CONTROLS
Autore:
SHAW GL; WEIFFENBACH B; FALK RT; FRAME JN; ISSAQ HJ; MOIR DT; CAPORASO N;
Indirizzi:
UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,12902 MAGNOLIA DR TAMPA FL 33612 GENOME THERAPEUT CORP,DEPT HUMAN GENET & MOL BIOL WALTHAM MA 02154 NCI,DIV CANC EPIDEMIOL & GENET,NIH BETHESDA MD 20892 NATL NAVAL MED RES INST,DEPT INTERNAL MED,DIV MED ONCOL BETHESDA MD 20889 NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK FREDERICK MD 21701
Titolo Testata:
Lung cancer
fascicolo: 1, volume: 17, anno: 1997,
pagine: 61 - 68
SICI:
0169-5002(1997)17:1<61:FOTVAC>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
POOR METABOLIZERS; SPARTEINE POLYMORPHISM; DRUG-METABOLISM; POINT MUTATIONS; DEBRISOQUINE; GENE; SUSCEPTIBILITY; IDENTIFICATION; PHENOTYPE; DELETION;
Keywords:
DEBRISOQUINE; LUNG CANCER; GENETIC SUSCEPTIBILITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
16
Recensione:
Indirizzi per estratti:
Citazione:
G.L. Shaw et al., "FREQUENCY OF THE VARIANT ALLELE CYP2D6(C) AMONG NORTH-AMERICAN CAUCASIAN LUNG-CANCER PATIENTS AND CONTROLS", Lung cancer, 17(1), 1997, pp. 61-68

Abstract

Previous reports of the association between the debrisoquine polymorphism and lung cancer risk are conflicting. Following the report of an association between lung cancer risk and the variant allele CYP2D6(C),we examined the presence of this allele in 98 incident Caucasian lungcancer patients and 110 age, race, and sex matched hospital controls from a case-control study conducted at the National Naval Medical Center in Bethesda, MD. Debrisoquine metabolic phenotype was determined bydebrisoquine administration and analysis of debrisoquine and 4-hydroxydebrisoquine in the subsequent 8 h urine collected. Genomic DNA was genotyped bs;a specific polymerase chain reaction amplification and subsequent restriction enzyme digestion, and Southern analysis. Twenty subjects were heterozygous for the CYP2D6(C) allele but none were homozygous for this allele. There was no significant difference in frequencyof CYP2D6(C) between lung cancer patients and controls (5.61% and 4.09%. respectively), and there was no significant heterogeneity among cases by histologic type of lung cancer (P = 0.08). However, 7 of 11 cases (64%) with the CYP2D6(C) allele had small cell lung cancer. and none had squamous cell carcinoma. Carrying the CYP2D6(C) allele did nut impair debrisoquine metabolism to the same degree as the known inactivating mutations, CYP2D6(A) and CYP2D6(B), or deletion of CYP2D6. Thus, the CYP2D6(C) allele does not encode a completely inactivating mutation, and the suggestion of a role for this variant allele in the risk for specific histologic types of lung cancer justifies further investigation. (C) 1997 Elsevier Science Ireland Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 07:01:31